Ignite Creation Date:
2025-12-25 @ 12:14 AM
Ignite Modification Date:
2025-12-25 @ 10:16 PM
Study NCT ID:
NCT06716658
Status:
RECRUITING
Last Update Posted:
2025-11-18
First Post:
2024-11-29
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-12-25
Start Date Type:
ACTUAL
Primary Completion Date:
2026-11-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-11-15
Completion Date Type:
ESTIMATED
First Submit Date:
2024-11-29
First Submit QC Date:
None
Study First Post Date:
2024-12-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-14
Last Update Post Date:
2025-11-18
Last Update Post Date Type:
ESTIMATED